Stockscreener 앱 받기
10.37
2.12%
-0.2449
전일 마감가:
$10.61
열려 있는:
$10.44
하루 거래량:
224.34K
Relative Volume:
0.08
시가총액:
$1.37B
수익:
-
순이익/손실:
$-766.97M
주가수익비율:
-1.3531
EPS:
-7.66
순현금흐름:
$-646.43M
1주 성능:
-6.86%
1개월 성능:
-3.48%
6개월 성능:
-34.56%
1년 성능:
-66.47%
1일 변동 폭
$10.35
$10.63
1주일 범위
$10.15
$11.91
52주 변동 폭
$7.48
$31.80
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.36 | 1.41B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.14 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.00 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.39 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com
RBC Raises Price Target on Biohaven to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. Common Shares (NY: BHVN - The Chronicle-Journal
Biohaven Ltd reports results for the quarter ended September 30Earnings Summary - TradingView
Biohaven (NYSE:BHVN) Announces Earnings Results - MarketBeat
Biohaven (NYSE: BHVN) refocuses pipeline after key trial and FDA setbacks - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q4 Adjusted Loss $0.90 per Share, vs. FactSet Est of $-0.87 - marketscreener.com
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors - Sahm
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
BHVN Should I Buy - Intellectia AI
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Navigating a Potential 80% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (BHVN) Edition - Stock Traders Daily
Biohaven (BHVN) Projected to Post Earnings on Monday - MarketBeat
Is Biohaven Ltd. stock a good pick for beginnersWeekly Trade Report & Expert Curated Trade Setup Alerts - mfd.ru
Biohaven Ltd. (BHVN) Stock Analysis: A Biotech Challenger With An 84% Potential Upside - DirectorsTalk Interviews
Raymond James Begins Coverage of Biohaven with Strong Buy Rating and Sets Price Target at $75 - Intellectia AI
What catalysts could drive Biohaven Ltd. stock higherTrade Exit Summary & Real-Time Volume Analysis - mfd.ru
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026 - Intellectia AI
Biohaven Reveals Pricing for $175 Million Public Offering of Common Stock - Intellectia AI
Aug Drivers: Is Biohaven Ltd. in a bullish channelWeekly Trend Recap & Safe Entry Trade Reports - mfd.ru
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments - Fierce Biotech
(BHVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Biohaven Stock Surges 8.4% After Analyst Upgrade - National Today
Assessing Biohaven (BHVN) Valuation As Analyst Optimism And Earnings Estimates Improve - simplywall.st
RSI Check: Can Biohaven Ltd deliver alpha2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Biohaven Ltd. (BHVN): Analyst Consensus Points to 63% Upside Potential Amidst Biotech Innovation - DirectorsTalk Interviews
Does Biohaven Ltd. (BHVN) have the potential to rally 82.16% as Wall Street analysts expect? - MSN
Big Money Moves: What are analysts price targets for Biohaven LtdWall Street Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Is Biohaven Ltd. (BHVN) stock outpacing its medical peers this year? - MSN
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Biohaven (NYSE:BHVN) Stock Price Up 8.4%Should You Buy? - MarketBeat
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect? - Finviz
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
자본화:
|
볼륨(24시간):